Mercato europeo della narcolessia fino al 2027 – Analisi regionale e previsioni per tipologia (narcolessia con cataplessia, narcolessia senza cataplessia e narcolessia secondaria); Prodotto (stimolanti del sistema nervoso centrale (SNC), sodio oxibato e antidepressivi); Canale distributivo (Farmacie ospedaliere e Farmacie al dettaglio) e Paese
Si prevede che il mercato europeo della narcolessia raggiungerà 1.532,5 milioni di dollari nel 2027 rispetto a 671,1 milioni di dollari nel 2018. Si prevede che il mercato della narcolessia aumenterà con un CAGR del 9,7% nel periodo 2019-2027. .
Si stima che il mercato della narcolessia crescerà a causa dei fattori chiave fattori trainanti come la crescente ricerca e sviluppo e la crescente consapevolezza in tutta la regione. Tuttavia, è probabile che fattori come le sfide legate alla narcolessia agiscano come un importante fattore frenante per la crescita del mercato.
< p>La narcolessia è un raro disturbo cronico del sonno causato dalla perdita dei neuroni che producono ipocretina. Sono stati fatti vari sviluppi per produrre medicinali in grado di ridurre i sintomi della narcolessia. Numerose ricerche e sviluppi vengono condotti in paesi come Germania, Regno Unito e altri paesi della regione europea. Ad esempio, nell\'aprile 2019, in Germania, sono state svolte attività di ricerca e sviluppo presso l\'Inserm e l\'Université di Montpellier. La ricerca è stata condotta in collaborazione con team internazionali che hanno contribuito a condurre studi epidemiologici e clinici per il farmaco Solriamfetol tra le persone che vivono con la narcolessia.
Inoltre, lo studio è stato condotto in collaborazione con Jazz Pharmaceuticals, la società ha investito nella sperimentazione e detiene anche una licenza per sviluppare e commercializzare Solriamfetol. Lo studio era una sperimentazione clinica di fase III e i risultati hanno mostrato che il farmaco non ha effetti collaterali per i pazienti che convivono con la narcolessia. Pertanto, a causa delle crescenti attività di ricerca e sviluppo per la narcolessia, è probabile che aumenti la crescita del mercato durante il periodo di previsione.
span>
Entrate e previsioni del mercato della narcolessia in Germania fino al 2027 (milioni di dollari)
< /span>
Narcolessia europea: – Segmentazione del mercato
Mercato europeo della narcolessia: – Per tipo
Narcolessia con cataplessia
Narcolessia senza cataplessia
Narcolessia secondaria
Mercato europeo - Per prodotto
Stimolanti del sistema nervoso centrale (SNC)
Oxibato di sodio
Antidepressivi
Mercato europeo - Per canale di distribuzione
Farmacie ospedaliere
Farmacie al dettaglio
Per area geografica
Europa
Stati Uniti
Canada
Messico
Profili aziendali
Teva Pharmaceutical Industries Ltd.
Jazz Pharmaceuticals plc< /span>
Arena Pharmaceuticals, Inc.
Graymark Healthcare, Inc.
Novartis AG
Takeda Pharmaceutical Company Limited
Mylan NV
BIOPROJET
Shionogi & Co., Ltd.
Ligand Pharmaceuticals, Inc
Europe Narcolepsy Strategic Insights
Strategic insights for Europe Narcolepsy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Get more information on this report
Europe Narcolepsy Report Scope
Report Attribute
Details
Market size in 2018
US$ 671.1 Million
Market Size by 2027
US$ 1,532.5 Million
Global CAGR (2019 - 2027)
9.7%
Historical Data
2016-2017
Forecast period
2019-2027
Segments Covered
By Tipo
Narcolessia con cataplessia
Narcolessia senza cataplessia
Narcolessia secondaria
By Prodotto
Stimolanti del sistema nervoso centrale
sodio oxibato
antidepressivi
By Canale di distribuzione
farmacie ospedaliere
farmacie al dettaglio
Regions and Countries Covered
Europa
Regno Unito
Germania
Francia
Russia
Italia
resto Europa
Market leaders and key company profiles
Teva Pharmaceutical Industries Ltd.
Jazz Pharmaceuticals plc
Arena Pharmaceuticals, Inc.
Graymark Healthcare, Inc.
Novartis AG
Takeda Pharmaceutical Company Limited
Mylan N.V.
BIOPROJET
Shionogi & Co., Ltd.
Ligand Pharmaceuticals, Inc
Get more information on this report
Europe Narcolepsy Regional Insights
The regional scope of Europe Narcolepsy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
Get more information on this report
Identical Market Reports with other Region/Countries
The Europe Narcolepsy Market is valued at US$ 671.1 Million in 2018, it is projected to reach US$ 1,532.5 Million by 2027.
What is the CAGR for Europe Narcolepsy Market by (2019 - 2027)?
As per our report Europe Narcolepsy Market, the market size is valued at US$ 671.1 Million in 2018, projecting it to reach US$ 1,532.5 Million by 2027. This translates to a CAGR of approximately 9.7% during the forecast period.
What segments are covered in this report?
The Europe Narcolepsy Market report typically cover these key segments-
Tipo (Narcolessia con cataplessia, Narcolessia senza cataplessia, Narcolessia secondaria)
Prodotto (Stimolanti del sistema nervoso centrale, sodio oxibato, antidepressivi)
Canale di distribuzione (farmacie ospedaliere, farmacie al dettaglio)
What is the historic period, base year, and forecast period taken for Europe Narcolepsy Market?
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Narcolepsy Market report:
Historic Period : 2016-2017
Base Year : 2018
Forecast Period : 2019-2027
Who are the major players in Europe Narcolepsy Market?
The Europe Narcolepsy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
Teva Pharmaceutical Industries Ltd.
Jazz Pharmaceuticals plc
Arena Pharmaceuticals, Inc.
Graymark Healthcare, Inc.
Novartis AG
Takeda Pharmaceutical Company Limited
Mylan N.V.
BIOPROJET
Shionogi & Co., Ltd.
Ligand Pharmaceuticals, Inc
Who should buy this report?
The Europe Narcolepsy Market report is valuable for diverse stakeholders, including:
Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.
Essentially, anyone involved in or considering involvement in the Europe Narcolepsy Market value chain can benefit from the information contained in a comprehensive market report.
Personal & transactional information is kept safe from unauthorized use.
WHAT'S INCLUDED IN FULL REPORT : Market Dynamics,
Competitive Analysis and Assessment, Define Business Strategies, Market Outlook and
Trends, Market Size and Share Analysis, Growth Driving Factors, Future Commercial
Potential, Identify Regional Growth Engines